^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ROCK inhibitor

    Related drugs:
    Associations

    News

    Trials
    21h
    CLARA: A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) (clinicaltrials.gov)
    P1/2, N=97, Completed, Aurion Biotech | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Apr 2025
    Trial completion • Trial completion date
    1d
    TQ05105-Ⅱ-01: A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis (clinicaltrials.gov)
    P2, N=107, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Feb 2026
    Enrollment closed • Trial completion date
    |
    JAK2 (Janus kinase 2)
    |
    hydroxyurea • rovadicitinib (TQ05105)
    1d
    DETECT I: Descemet Endothelial Thickness Comparison Trial I (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting
    Enrollment closed
    6d
    A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets (clinicaltrials.gov)
    P1, N=40, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Completed
    Trial completion
    |
    itraconazole • rifampicin • rovadicitinib (TQ05105)
    10d
    A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) (clinicaltrials.gov)
    P1/2, N=13, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    rovadicitinib (TQ05105)
    15d
    A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026
    Trial completion date
    |
    rovadicitinib (TQ05105)
    16d
    Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer. (PubMed, Cancer Res)
    Treatment with fasudil, a Rho kinase inhibitor, effectively blocked mitochondrial transfer and restored sensitivity to the EGFR-TKI osimertinib in vivo. Together, this work reveals targetable stromal-tumor crosstalk that sustains DTP populations, proposing a combination therapy for overcoming EGFR-TKI resistance.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • RHOA (Ras homolog family member A) • CCL11 (C-C Motif Chemokine Ligand 11)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib)
    23d
    The effects of baicalin on blood lipid metabolism and immune function in rats with gestational diabetes mellitus based on RhoA/ROCK pathway (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
    GDM rats were randomly divided into a model group, a fasudil (FA) (RhoA/RocK inhibitor) group (10 mg/kg), low-dose (100 mg/kg) and high-dose (200 mg/kg) baicalin groups, and a high-dose baicalin combined with LPA (RhoA/RocK activator) group (200 mg/kg baicalin+1 mg/kg LPA ), with 12 rats in each group...LPA could obviously weaken the improvement effects of baicalin on blood lipid metabolism and immune function in GDM rats. Conclusion Baicalin may improve blood lipid metabolism and immune function in GDM rats by inhibiting the RhoA/ROCK pathway.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • RHOA (Ras homolog family member A) • ROCK1 (Rho Associated Coiled-Coil Containing Protein Kinase 1)
    24d
    A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) (clinicaltrials.gov)
    P3, N=110, Completed, Kowa Research Institute, Inc. | Active, not recruiting --> Completed
    Trial completion
    1m
    GLR305-E001: Next Generation Rocklatan (clinicaltrials.gov)
    P2, N=426, Completed, Alcon Research | Active, not recruiting --> Completed
    Trial completion
    1m
    Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (clinicaltrials.gov)
    P4, N=35, Recruiting, Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment (clinicaltrials.gov)
    P1/2, N=48, Recruiting, Massachusetts Eye and Ear Infirmary | Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment open • Trial completion date • Trial primary completion date